About Leucine-rich repeat-containing protein 2
Leucine-rich repeat-containing protein 2 (LRRC2) is a protein
from Homo sapiens identified by UniProt accession
Q9BYS8, 371 residues long.
MolForge cross-references it against 0 known binders and
51 disease associations.
Target properties
| Protein name | Leucine-rich repeat-containing protein 2 |
| UniProt accession | Q9BYS8 |
| Gene | LRRC2 |
| Organism | Homo sapiens |
| Length | 371 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (51)
Diseases linked to this target (Open Targets).
- blood protein measurement · score 0.29
- teratocarcinoma-derived growth factor 1 measurement · score 0.25
- protein measurement · score 0.24
- macrophage inflammatory protein 1b measurement · score 0.23
- cerebrospinal fluid biomarker measurement · score 0.19
- age at diagnosis · score 0.18
- coronary atherosclerosis · score 0.18
- Mumps virus infectious disease · score 0.17
- CCL4 measurement · score 0.15
- body height · score 0.12
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9BYS8-F1 | alphafold | PREDICTED | 77.59 | — |
Amino-acid sequence (371 residues)
MGHKVVVFDI SVIRALWETR VKKHKAWQKK EVERLEKSAL EKIKEEWNFV AECRRKGIPQ AVYCKNGFID TSVRLLDKIE RNTLTRQSSL PKDRGKRSSA FVFELSGEHW TELPDSLKEQ THLREWYISN TLIQIIPTYI QLFQAMRILD LPKNQISHLP AEIGCLKNLK ELNVGFNYLK SIPPELGDCE NLERLDCSGN LELMELPFEL SNLKQVTFVD ISANKFSSVP ICVLRMSNLQ WLDISSNNLT DLPQDIDRLE ELQSFLLYKN KLTYLPYSML NLKKLTLLVV SGDHLVELPT ALCDSSTPLK FVSLMDNPID NAQCEDGNEI MESERDRQHF DKEVMKAYIE DLKERESVPS YTTKVSFSLQ L
Explore Leucine-rich repeat-containing protein 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets